Purine derivatives as ligands for A3 adenosine receptors

Current Topics in Medicinal Chemistry

Volumn 5, Issue 13, 2005, Pages 1275-1295

  Joshi, Bhalchandra V ^a   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

7TM receptor; Agonist; Antagonist; Purine; Radioligand; Tissue protection

Indexed keywords

1 ACETYL 2,3,5 TRI O BENZOYLRIBOFURANOSIDE; 1' O ACETYLIBOSIDE DERIVATIVE; 1,2 O ISOPROPYLIDENE XYLOFURANOSE; 2 (N 3 METHYL 1 BUTYLIDENEHYDRAZINO)ADENOSINE DERIVATIVE; 2 IODOADENOSINE DERIVATIVE; 2 NITROADENOSINE DERIVATIVE; 6 CHLOROPURINE 9 RIBOSIDE; ADENINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE 5' (N METHYLCARBOXAMIDE); ADENOSINE A3 RECEPTOR; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; AMIDE; CP 608039; CYCLOPENTENONE DERIVATIVE; IODINE 6 N (4 AMINO 3 IODOBENZYL) 5' N METHYLCARBOXAMIDOADENOSINE I 125; ISOXAZOLE DERIVATIVE; LIGAND; METHYL 1 [6 N (3 IODOBENZYL)ADENIN 9 YL] BETA RIBOFURONAMIDE; NNC 53 0082; NNC 53 0083; NUCLEOSIDE DERIVATIVE; PURINE DERIVATIVE; RIBOSE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; XANTHINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; CLINICAL TRIAL; COLON CARCINOMA; CYCLOPROPANATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; LIGANDS; MOLECULAR CONFORMATION; PURINES; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 29444452024     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802605774463079     Document Type: Review

References (65)

1. Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Klotz, K.N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of ARs. Pharmacol. Rev. 2001, 53, 527-552.
2. 3 adenosine receptor. Proc. Nat. Acad. Sci. USA 1993, 90, 10365-10369.
3. 3 receptors: novel ligands and paradoxical effects. Trends Pharmacol. Sci. 1998, 19, 184-191.
4. Jacobson, K.A.; Kim, S.K.; Costanzi, S.; Gao, Z.G. Purine receptors: GPCR structure and agonist design. Mol. Interv. 2004, 4, 337-347.
5. 3-selective adenosine agonists. J. Med. Chem. 1994, 37, 636-646.
6. Klotz, K.N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B.B.; Lohse, M.J. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch. Pharmacol. 1998, 357, 1-9.
7. 3 adenosine receptors. Biochem. Pharmacol. 2003, 65, 1675-168.
8. 3 adenosine receptor. Proc Natl. Acad. Sci. USA 1992, 89, 7432-7436.
9. 3 adenosine receptors. Biochem Biophys Res Commun. 1994, 203, 570-576.
10. 3 adenosine receptor. Mol. Pharmacol. 1994, 45, 1101-1111.
11. 3-adenosine receptors. J. Med. Chem. 1994, 37, 3614-3621.
12. 3 adenosine receptor. Mol. Pharmacol. 1994, 45, 978-982.
13. 3 selective ligands containing bioisosteric isoxazoles. Bioorg. Med. Chem. Lett. 1998, 13, 1767-1770.
14. 3 adenosine receptors. J. Med. Chem. 1996, 39, 802-806.
15. 3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. J. Med. Chem. 1994, 37, 4020-4030.
16. 3 receptor. J. Med. Chem. 2002, 45, 420-429.
17. 3 receptor subtypes. Bioorg. Med. Chem. Lett. 2000, 10, 2141-2144.
18. 3 adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol. 1999, 360, 103-108.
19. Ohno, M.; Gao, Z.G.; Van Rompaey, P.; Tchilibon, S.; Kim S.K.; Harris, B.A.; Gross, A.S.; Duong, H.T.; Van Calenbergh, S.; Jacobson, K.A. Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position Bioorg. Med. Chem. 2004, 12, 2995-3007.
20. 3 receptor agonists. J. Med. Chem. 2004, 47, 4766-4773.
21. 3 receptor. J. Med. Chem. 2003, 46, 353-355.
22. 3 receptor ligands. Bioorg. Med. Chem. Lett. 2003, 13, 817-820.
23. 3 receptor with selectively enhanced affinity for amine-modified nucleosides. J. Med. Chem. 2001, 44, 4125-4136.
24. 3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety. Bioorg. Med. Chem. 2005, 13, 973-983.
25. 3 adenosine receptor. J. Med. Chem. 2003, 46, 3775-3777.
26. Jacobson, K.A.; Ji, X.; Li, A.H.; Melman, N.; Siddiqui, M.A.; Shin, K.J.; Marquez, V.E.; Ravi, R.G. Methanocarba analogues of purine nucleosides as potent and selective AR agonists. J. Med. Chem. 2000, 43, 2196-2203.
27. 2A receptor agonist, on native IKr and cloned HERG current. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370, 492-499.
28. Jeong, L.S.; Marquez, V.E.; Yuan, C.-S.; Borchardt, R.T. 4′,1′a Methanocarbocyclic adenosine analogues as potential inhibitors of S-adenosylhomocysteine hydrolase. Heterocycles, 1995, 41, 2651-2656.
29. Lee, K.; Ravi, G.; Ji, X.D.; Marquez, V.E.; Jacobson, K.A. Ring-constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5′-uronamide and 2′-deoxy modifications. Bioorg. Med. Chem. Lett. 2001, 11, 1333-1337.
30. 3 adenosine receptor agonists. J. Org. Chem., 2005, 70, 439-447.
31. 3 adenosine receptor agonists. J. Med. Chem. 2005, 48, 1745-1758.
32. 3 adenosine receptor antagonists J. Med. Chem. 2002, 45, 3337-3344.
33. 3 adenosine receptors. J. Med. Chem. 1995, 38, 1720-1735.
34. 3 adenosine receptor antagonists. J. Med. Chem. 2005, 48, 4910-4918.
35. 3 adenosine receptors. Curr. Top. Med. Chem. 2004, 4, 855-862.
36. Gao, Z.G.; Mamedova, L.; Chen, P.; Jacobson, K.A. 2-Substituted adenosine derivatives: Affinity and efficacy at four subtypes of human adenosine receptors. Biochem. Pharmacol. 2004, 68, 1985-1993.
37. 3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J. Med. Chem. 2002, 45, 4471-4484.
38. 6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg. Med. Chem. 2004, 12, 2021-2034.
39. Moro, S.; Spalluto, G.; Gao, Z.G.; Jacobson, K.A. Progress in pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev. (in press).
40. 3 adenosine receptors. Bioorg. Med. Chem. Lett. 2000, 10, 209-211.
41. 3 adenosine receptors. Bioorg Med. Chem Lett. 2002, 12, 501-503.
42. 3 adenosine receptors. J. Immunol. 1996, 156, 3435-3442.
43. 3 receptor: Sustained cardioprotection Proc. Nat. Acad. Sci. USA 1998, 95, 6995-6999.
44. 3 receptors and cerebroprotection in stroke. Ann. N.Y.Acad.Sci. 2001, 939, 85-96.
45. 3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 2002, 13, 437-443.
46. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 2000, 275, 4429-4434.
47. 3 receptors augments adenosine-induced coronary flow in isolated mouse heart. Am.J.Physiol. 2002, 282, 2183-2189
48. 3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell. Mol. Neurobiol. 2003, 23, 431-447.
49. 3 adenosine receptors reduces mouse intraocular pressure. Invest. Ophthalmol. Vis. Sci. 2002, 43, 3021-3026.
50. 3 receptor ligands. J. Med. Chem. 2002, 45, 3703-3708.
51. 3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg. Med. Chem. Lett. 2004, 14, 3775-3779.
52. Fozard, J.R.; McCarthy, C. Adenosine receptor ligands as potential therapeutics in asthma. Curr. Opin. Investig. Drugs 2002, 3, 69-77.
53. 3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993, 336, 57-60.
54. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 1994, 263, 59-67.
55. 3 adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ. Res. 2001, 88, 520-528.
56. 3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur. J. Pharmacol. 1996, 308, 311-314.
57. 3 adenosine receptor. Circ. Res. 1996, 78, 627-634.
58. 3 receptors promote degranulation of rat mast cells both in vitro and in vivo. Inflamm. Res. 1997, 461, 80-84.
59. 3 receptor-mediated hypotension and mast cell degranulation in the rat by dexamethasone. J. Pharmacol. Exp. Ther. 2002, 302, 725-730.
60. 3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo. Cell. Mol. Biol. (Noisy-le-grand). 1997, 43, 345-349.
61. 3 adenosine receptor agonists Neoplasia 2001, 3, 125-131.
62. 3 receptor-mediated potentiation of mucociliary transport and epithelial ciliary motility. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 282, L556-562.
63. 3 adenosine receptors: Modification of the ribose moiety. Biochem. Pharmacol. 2004, 67, 893-901.
64. 3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Current Eye Res. 2005, 30, 747-754.
65. 2B ligands. J. Med. Chem. 2002, 45, 3271-3279.